Observational studyJournal of assisted reproduction and genetics2025
Pharmacogenetic analysis using artificial intelligence (AI) to identify polymorphisms associated with sub-optimal ovarian response and hyper-response.
Observational study in Journal of assisted reproduction and genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Artificial intelligence in ovarian pathophysiology and management: a systematic review and meta-analysis.Journal of ovarian research · 2026Pooled it
- Implementation readiness of artificial intelligence inFrontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo identify genetic variants associated with an increased likelihood of sub-optimal ovarian response or hyper-response by machine learning.
methodsThis retrospective observational study, conducted between March 2018 and April 2022, analyses 495 ovarian stimulations in oocyte donors. Only each donor's first ovarian stimulation was considered. The egg donors were healthy women aged 18 to 35 years. Donor characteristics and ovarian stimulation data were recorded, as well as genotypes of 31 polymorphisms previously identified as modulators of ovarian response. Models to predict the type of ovarian response (sub-optimal, normal, or hyper-response) were performed using 5 different classification machine-learning algorithms. The most important variables were determined by SHAP (Shapley-Additive-exPlanations) values.
resultsDespite being young with good ovarian reserves and using similar stimulation protocols, 15.15% of oocyte donors had a sub-optimal response (4-9 oocytes), while 27.27% showed a hyper-response (over 20 oocytes). The best predictive model was random forest, with an AUC of 0.822. Six significant genetic polymorphisms were identified: three in hormone receptors-oestrogen receptor (ESR2; c.*39G > A, c.984G > A), follicle-stimulating hormone receptor (FSHR; p.Asn680Ser, c.-29G > A), and AMH receptor (AMHR2; c.622-6C > T) and one in growth differentiation factor 9 (GDF9; c.398-39G > C). Four polymorphisms (ESR2, FSHR) were linked to sub-optimal response, while two (AMHR2, GDF9) were associated with hyper-response.
conclusionsBy using a predictive model to asses ovarian response, we identified six genetic polymorphisms associated with ovarian response. Women who carry these genetic variants may be suitable candidates for personalised ovarian stimulation treatments to help prevent inadequate responses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.